Physician profile
Albert Schenone
NPI 1417924390
$3,190.86
in general payments reported to CMS, 2019-2025
13 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $195 · 2021: $413 · 2022: $557 · 2023: $334 · 2024: $795 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,072.15 | 2019-2025 | Acticor 7 Vr-T Dx, Selectra, Amvia Edge |
| Impulse Dynamics (USA) INC. | $419.81 | 2021-2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $383.72 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $240.35 | 2024 | Gore Septal Occluder |
| Janssen Pharmaceuticals, INC | $202.16 | 2019-2024 | Xarelto |
| Abbott Laboratories | $149.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $129.85 | 2019-2023 | Eliquis |
| Vivaquant INC, Dba Rhythm Express | $129.84 | 2025 | Rhythm Express |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Zoll Respicardia, INC. | $124.88 | 2020 | |
| Medtronic, INC. | $99.40 | 2023 | Corevalve Evolut R |
| Medtronic Vascular, INC. | $93.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Schenone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.